Tracking an antibody response in severe hemophilia A on emicizumab
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial studies how your body’s anti-factor VIII antibodies change while you are treated with emicizumab for severe hemophilia A. The goal is to better understand the immune response during treatment and whether it relates to how well therapy works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have severe congenital hemophilia A
- You are currently being treated with emicizumab
- You will provide informed consent to join the study
- You are not taking immunosuppressive medicines (medicine that lowers your immune system)
- If you have HIV, your CD4 count is 200 or higher
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if switching from emicizumab to a new medicine called marstacimab is safe and effective for people with severe hemophilia A. You must have been on emicizumab for at least 6 months and not have a history of blood clots or heart disease.
This study collects real-world information on how well a personalized clotting-factor plan helps people with hemophilia A get rid of inhibitors. It may help doctors refine treatment for patients who develop antibodies that block factor therapy.
This study tests a new approach to immune tolerance induction (ITI) in young people with severe hemophilia A who have a high-titer inhibitor. It uses a specific clotting factor combined with emicizumab to try to retrain the immune system so that standard treatments work again.
This trial compares two low-dose medicines to prevent bleeding episodes in people with severe hemophilia A: a newer medicine (emicizumab) versus the standard factor VIII treatment. It may help find a more convenient or effective way to reduce bleeding.
This study tests a medicine called emicizumab, given as a shot under the skin, to see how well it works in children with hemophilia A. It may help prevent bleeding episodes and improve quality of life.
This trial tests if a new medicine, NXT007, is better than emicizumab at preventing bleeding episodes in people with hemophilia A. It may be an option for those with or without inhibitors who are willing to switch to a preventive treatment.
Hear when a new Severe Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.